Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference

Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates ...
Investing

Atea Pharmaceuticals Q2 2025 slides: HCV program advances with Phase 3 trials underway

HCV Program Progress and Clinical Data The BEM/RZR combination demonstrated impressive efficacy in Phase 2 trials, achieving a 98% sustained virologic response at 12 weeks post-treatment (SVR12) in ...
Yahoo Finance

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...
Monthly Prescribing Reference

Benefits of Simplified HCV Treatment Program Investigated

The study, which was an open multi-cohort Markov model, aimed to analyze the clinical and economic outcomes of the United States HCV population from 2018 on. For patients with non-cirrhotic chronic ...
Nasdaq

Atea Pharmaceuticals Advances HCV Treatment with Ongoing Phase 3 C-BEYOND Trial and Promising Phase 2 Results for Bemnifosbuvir and Ruzasvir at EASL 2025

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
Nasdaq

Atea Pharmaceuticals Launches Phase 3 C-FORWARD Trial for HCV Treatment Regimen Combining Bemnifosbuvir and Ruzasvir

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...
Healio

HCV telemedicine program satisfying, cost-effective in Spanish prison

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — A telemedicine program brought high levels of satisfaction and proved cost effective in patients ...